The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
By Prakash Ambady, MD
FDA grants accelerated approval to dordaviprone, the first systemic therapy for diffuse midline glioma with an H3 K27M mutation, offering new hope for patients after progression on prior treatment.
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
By Prakash Ambady, MD
FDA grants accelerated approval to dordaviprone, the first systemic therapy for diffuse midline glioma with an H3 K27M mutation, offering new hope for patients after progression on prior treatment.
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
By Prakash Ambady, MD
FDA grants accelerated approval to dordaviprone, the first systemic therapy for diffuse midline glioma with an H3 K27M mutation, offering new hope for patients after progression on prior treatment.
Breakthrough Study Shows CAR T Cells Can Be Generated Inside The Body
By The Cancer News Team
Researchers have developed a new method for generating CAR T cells inside the body using targeted lipid nanoparticles, potentially eliminating barriers that contribute to cancer health disparities.
Breakthrough Study Shows CAR T Cells Can Be Generated Inside The Body
By The Cancer News Team
Researchers have developed a new method for generating CAR T cells inside the body using targeted lipid nanoparticles, potentially eliminating barriers that contribute to cancer health disparities.
Breakthrough Study Shows CAR T Cells Can Be Generated Inside The Body
By The Cancer News Team
Researchers have developed a new method for generating CAR T cells inside the body using targeted lipid nanoparticles, potentially eliminating barriers that contribute to cancer health disparities.
Can Exercise Save Lives After Colon Cancer? New Study Suggests It Might
By The Cancer News Team
A landmark phase 3 trial shows structured exercise after chemotherapy significantly improves survival and reduces recurrence in colon cancer patients.
Can Exercise Save Lives After Colon Cancer? New Study Suggests It Might
By The Cancer News Team
A landmark phase 3 trial shows structured exercise after chemotherapy significantly improves survival and reduces recurrence in colon cancer patients.
Can Exercise Save Lives After Colon Cancer? New Study Suggests It Might
By The Cancer News Team
A landmark phase 3 trial shows structured exercise after chemotherapy significantly improves survival and reduces recurrence in colon cancer patients.
Centering Cancer Patients’ Voices in Global Health Advocacy
By Sujata Ojha, MD
Centering patient voices in global oncology, Dr. Sujata Ojha explores how equitable cancer care depends on grassroots advocacy and inclusive health systems.
Centering Cancer Patients’ Voices in Global Health Advocacy
By Sujata Ojha, MD
Centering patient voices in global oncology, Dr. Sujata Ojha explores how equitable cancer care depends on grassroots advocacy and inclusive health systems.
Centering Cancer Patients’ Voices in Global Health Advocacy
By Sujata Ojha, MD
Centering patient voices in global oncology, Dr. Sujata Ojha explores how equitable cancer care depends on grassroots advocacy and inclusive health systems.
National Cancer Survivors Day 2025: Stories, Support, and What Comes Next
By The Cancer News Team
Celebrating resilience, this article explores the stories, support systems, and survivorship challenges faced by millions on National Cancer Survivors Day 2025.
National Cancer Survivors Day 2025: Stories, Support, and What Comes Next
By The Cancer News Team
Celebrating resilience, this article explores the stories, support systems, and survivorship challenges faced by millions on National Cancer Survivors Day 2025.
National Cancer Survivors Day 2025: Stories, Support, and What Comes Next
By The Cancer News Team
Celebrating resilience, this article explores the stories, support systems, and survivorship challenges faced by millions on National Cancer Survivors Day 2025.
President Joe Biden’s Prostate Cancer Diagnosis: Can It Be Cured?
By Dr. Jordan Ciuro
Dr. Jordan Ciuro explores President Biden’s prostate cancer diagnosis, the evolving role of screening, and the latest immunotherapy options in prostate cancer care.
President Joe Biden’s Prostate Cancer Diagnosis: Can It Be Cured?
By Dr. Jordan Ciuro
Dr. Jordan Ciuro explores President Biden’s prostate cancer diagnosis, the evolving role of screening, and the latest immunotherapy options in prostate cancer care.
President Joe Biden’s Prostate Cancer Diagnosis: Can It Be Cured?
By Dr. Jordan Ciuro
Dr. Jordan Ciuro explores President Biden’s prostate cancer diagnosis, the evolving role of screening, and the latest immunotherapy options in prostate cancer care.
Binaytara Nepal Healthcare Policy Debate
By The Cancer News Team
This article recaps a 2025 advocacy dialogue led by Binaytara and Dr. Binay Shah to reform Nepal’s health insurance system and expand access to cancer care.
Binaytara Nepal Healthcare Policy Debate
By The Cancer News Team
This article recaps a 2025 advocacy dialogue led by Binaytara and Dr. Binay Shah to reform Nepal’s health insurance system and expand access to cancer care.
Binaytara Nepal Healthcare Policy Debate
By The Cancer News Team
This article recaps a 2025 advocacy dialogue led by Binaytara and Dr. Binay Shah to reform Nepal’s health insurance system and expand access to cancer care.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.